Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08RMJ
|
|||
| Former ID |
DCL000123
|
|||
| Drug Name |
GSK461364
|
|||
| Synonyms |
GSK461364; 929095-18-1; GSK-461364; 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide; GSK 461364; UNII-8QO27TK6Q4; GSK-461364A; (R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide; 8QO27TK6Q4; CHEMBL1908394; GSK461364A; ZHJGWYRLJUCMRT-QGZVFWFLSA-N; SCHEMBL310080; GTPL5684; C27H28F3N5O2S; CTK8B7590; CHEBI:91333; DTXSID60239197; MolPort-016-633-304; BCP01720; GSK 461364A
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1 | [1], [2] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H28F3N5O2S
|
|||
| Canonical SMILES |
CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)CN5CCN(CC5)C)C(=O)N
|
|||
| InChI |
1S/C27H28F3N5O2S/c1-17(19-5-3-4-6-20(19)27(28,29)30)37-23-14-24(38-25(23)26(31)36)35-16-32-21-8-7-18(13-22(21)35)15-34-11-9-33(2)10-12-34/h3-8,13-14,16-17H,9-12,15H2,1-2H3,(H2,31,36)/t17-/m1/s1
|
|||
| InChIKey |
ZHJGWYRLJUCMRT-QGZVFWFLSA-N
|
|||
| CAS Number |
CAS 929095-18-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
24263067, 26572720, 36167750, 104253513, 124757636, 125164440, 125329952, 126626057, 134339026, 136340307, 136348744, 136367599, 136920398, 136925373, 136959524, 137275956, 137823748, 144116034, 152043964, 152258842, 152344042, 160647692, 160825274, 162011970, 162037807, 162112773, 162202557, 163092504, 163384233, 163790355, 163908020, 170559064, 172650598, 177749072, 178102311, 184816415, 198971762, 204387978, 223685474, 224143985, 226649362, 243102726, 249582966, 252160365
|
|||
| ChEBI ID |
CHEBI:91333
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5684). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026258) | |||
| REF 3 | Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.